Brind.

Company Reports Revenue Decline, Raises 2026 Guidance

1 report, 1 independent Updated Nov 6
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The company reported total revenue of $381.4 million, a 5% decrease compared to the previous year, primarily due to lower ELEVIDYS sales volumes. Net Product Revenue fell 13% year over year, attributed to the ambulatory-only label for ELEVIDYS. Despite this, the company raised its 2026 revenue guidance to $1.25 billion to $1.30 billion, and narrowed its 2026 expense guidance to $800 million to $825 million. Non-GAAP Operating Income reached $22.9 million, improving from a non-GAAP operating loss of $35.7 million in the third quarter of 2025.

From aol.com

Why it matters

Some supportBrind's analysis of the reports

The financial results indicate a shift in revenue streams, with PMO Franchise Revenue supported by increasing new patient enrollments. The improvement in operating income and the raised revenue guidance suggest confidence in future performance despite current sales pressures.

From aol.com

Who's involved

  • James RichardsonChief Medical Officer, who was appointed on November 6, 2026
  • Hoffmann-La RocheSwiss healthcare company that provided a $40 million milestone payment to James Richardson

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • BlackstoneSpeculative

    Blackstone might see changes in valuation due to the reported shifts in revenue.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped